Posts With Tag clinical trials

AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.

AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.

AstraZeneca's latest SEC Form 6-K reveals promising results from the DESTINY-Breast11 trial, highlighting Enhertu's potential to redefine treatment for high-risk HER2-positive breast cancer patients.

Discover AstraZeneca's financial report on Calquence's EU approval for untreated CLL, highlighting significant trial results and market potential.

AstraZeneca's SEC report reveals the discontinuation of the CAPItello-280 trial for mCRPC. Discover the reasons, trial details, and future strategies in prostate cancer treatment.

Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.

Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.

Evaxion Biotech A/S files Form 6-K on Feb 25, 2025, announcing an extension of its EVX-01 cancer vaccine trial. Key for growth and market positioning in biotech.

Explore Cogent Biosciences' Q4 2023 financial results, highlighting significant net losses, cash position, and strategic recommendations for investors.

Explore AstraZeneca's SERENA-6 trial results on camizestrant, showing significant PFS improvement for HR-positive breast cancer. Discover its market potential and safety profile.

Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.

AstraZeneca's Form 6-K details the CALYPSO trial results for eneboparatide, indicating significant potential for treating chronic hypoparathyroidism. Key findings and next steps outlined.